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Severe infections are emerging as major risk factors for 
death among children with juvenile idiopathic arthritis (JIA). 
In particular, children with refractory JIA treated with long-
term, multiple, and often combined immunosuppressive 
and antiinflammatory agents, including the new biological 
disease-modifying antirheumatic drugs (DMARDs), are at 
increased risk for severe infections and death. We investi-
gated 4 persons with JIA who died during 1994–2013, three 
of overwhelming central venous catheter–related bacte-
rial sepsis caused by coagulase-negative Staphylococus or 
α-hemolytic Streptococcus infection and 1 of disseminated 
adenovirus and Epstein-Barr virus infection). All 4 had active 
JIA refractory to long-term therapy with multiple and com-
bined conventional and biological DMARDs. Two died while 
receiving high-dose systemic corticosteroids, methotrexate, 
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Infection and Juvenile Idiopathic Arthritis
and after recent exposure to anti–tumor necrosis factor-α 
biological DMARDs, and 2 during hematopoietic stem cell 
transplantation procedure. Reporting all cases of severe in-
fections and especially deaths in these children is of para-
mount importance for accurate surveillance.
Juvenile idiopathic arthritis (JIA), a group of clinically heterogonous conditions with arthritis of unknown ori-
gin beginning before 16 years of age and persisting for >6 
weeks, is the most common childhood chronic rheumatic 
disorder (1). The most severe forms are those with systemic 
(So-JIA) or polyarticular (poly-JIA) onset, progressing to 
polyarticular disease. Despite the success of conventional 
and new biological disease-modifying antirheumatic drugs 
(DMARDs), a substantial percentage (>30%) of patients 
will have ongoing active disease into adulthood that in-
cludes sequelae from chronic inflammation and consider-
able morbidity from joint damage, osteoporosis, growth 
retardation, psychosocial morbidity, and reduced quality of 
life and education or employment (2).
Rapidly evolving guidelines (3) include the window-
of-opportunity concept, where biological DMARDs are 
used as tailored therapy, depending on the disease category, 
and in naive patients not previously treated with conven-
tional DMARDs (e.g., corticosteroids) (2). In the United 
Kingdom, treatment guidelines are regulated by the Na-
tional Institute for Clinical Excellence, which specifies in-
dications for tumor necrosis factor-α (TNF-α), interleukin 
(IL) 6, T-cell activation, and IL-1 blocking agents (https://
www.nice.org.uk/guidance/ta373; https://www.nice.org.
uk/advice/esnm36). However, no good evidence exists to 
guide clinicians when they confront failure of the initial bi-
ological DMARD (4), and switching to a second (or third) 
(5) or combining >2 biological DMARDs (6) raises con-
cern about risks from severe infections and development of 
malignancy and new autoimmune disorders (7,8). For this 
small group of patients with refractory JIA, hematopoietic 
stem cell transplantation (HSCT) might be the only treat-
ment option (9).
We report details of 4 patients referred for HSCT be-
cause of refractory JIA who died of overwhelming infec-
tion from central venous catheter (CVC)–related bacterial 
sepsis (3 patients) or disseminated viral infection (1 pa-
tient). Two died while receiving high-dose systemic cor-
ticosteroids and methotrexate and after recent exposure to 
anti–TNF-α agents, before they underwent stem cell collec-
tion, and were not started on conditioning chemotherapy at 
the time of death; 2 died during HSCT (10,11).
Case Reports
Parents provided informed consent for data and tissue collec-
tion. Consent was obtained when the child started treatment 
with new anti–TNF-α agents (British Society for Paediatric 
and Adolescent Rheumatology database) or at assessment for 
HSCT (Newcastle upon Tyne Hospitals National Health Ser-
vice [NHS] Foundation Trust, Newcastle upon Tyne, UK).
Patient 1
Patient 1, a 13-year-old girl with refractory So-JIA who 
was previously reported with osteoarticular tuberculosis 
while treated with etanercept (12) (Table 1), never achieved 
complete disease control (Juvenile Arthritis Disease Activ-
ity Score [JADAS]–10 score 25–30) (Table 1) (13). She 
was assessed for HSCT on February 17, 2004 (Table 2). 
After CVC insertion for treatment with weekly intrave-
nous methylprednisolone pulses (IVMPs) and 1 dose of 
infliximab, routine CVC cultures grew fully sensitive 
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Table 1. Disease characteristics and treatment at time of death 
for 2 children with JIA, Newcastle upon Tyne, United Kingdom* 
Characteristic Patient 1 Patient 2 
Year of disease onset/year of death 1996/2004 2000/2004 
Age at So-JIA diagnosis/at death, y 5/13 2/6 
JIA symptom or sign, ever   
 Fever Yes Yes 
 Rash Yes Yes 
 Arthritis Yes Yes 
 Lymphadenopathy No No 
 Hepato/splenomegaly Yes Yes 
 Serositis No No 
 Macrophage activation syndrome No Yes 
Disease remission, ever No No 
JADAS-10† 20–35 12–32 
Treatment   
 Corticosteroids‡ Yes§ Yes§ 
 Methotrexate¶ Yes§ Yes§ 
 Cyclosporin A No Yes# 
 Intravenous immunoglobulins** No Yes†† 
 Etanercept Yes‡‡ No 
 Infliximab Yes§,§§ Yes§¶¶ 
Side effects of treatment   
 Cushingoid Yes Yes 
 Cataracts Yes No 
 Osteoporosis Yes Yes 
 Osteoarticular tuberculosis Yes No 
 Stunted growth Yes Yes 
*JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic 
arthritis; So-JIA, systemic JIA. 
†Linear sum of the scores of the 4 JADAS components (0–40): physician 
global assessment of disease activity (measured on a 10-cm visual analog 
scale; 0 = no activity and 10 = maximum activity); parent/patient global 
assessment of well-being (measured on a 10-cm visual analog scale; 0 = 
very well and 10 = very poor); count of joints with active disease (0–10); 
erythrocyte sedimentation rate (actual value/10; range 0–10) (13). 
‡Methylprednisolone pulses (intravenous 30 mg/kg/day; maximum. 1 g) 
given as a 3-day course or a single dose (weekly or otherwise), when 
indicated based on clinical decision (for treating a disease flare). 
Prednisolone maintenance dose (orally 0.5–1 mg/kg/d) with adjusting and 
aiming for alternate day regimen whenever possible depending on the 
clinical course or disease activity. 
§Treatment at time of death. 
¶Subcutaneously 15 mg/m2/wk. 
#March–December 2002. 
**2 g/kg/mo. 
††December 2003–January 2004. 
‡‡0.4 mg/kg/wk during March–May 2000 (12) and again during May 2003–
January 2004. 
§§5 mg/kg single dose, February 2004. 
¶¶6 mg/kg/mo during December 2002–December 2003. 
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coagulase-negative Staphylococcus. She was treated with 
systemic teicoplanin and vancomycin locks to all 3 CVC 
lumens for 7 days (15). On February 28, three days after 
antimicrobial treatment ended, she was readmitted with 
fever (40°C), generalized macular erythematous rash, 
abdominal discomfort, nausea, vomiting, and diarrhea. 
Alongside empirical treatment with systemic antimicrobial 
drugs (vancomicin and cefotaxime) and intravenous fluids, 
presumed adrenal insufficiency was treated with hydrocor-
tisone, but she remained febrile (38.6°C); on February 29, 
she had a sudden episode of hypotension (blood pressure 
70 mm Hg) requiring fluid bolus resuscitation and further 
hydrocortisone. On March 1, as the CVC was accessed for 
administration of antimicrobial drugs, she became pale and 
light-headed and collapsed; the CVC was removed, but she 
died of cardiorespiratory arrest. Multiple peripheral blood 
and CVC cultures taken during this period remained ster-
ile. Autopsy showed congested lungs and pleural effusions, 
atrophic adrenal glands, no identifiable thymus, and no 
erythrophagocytosis in liver or spleen. Cultures from the 
CVC tip, both lungs, and the pleural fluid samples taken 
post mortem grew α-hemolytic Streptococcus.
Patient 2
Patient 2, a 6-year-old girl, had refractory So-JIA (Table 
1) with macrophage activation syndrome (MAS), a form 
of hemophagocytic lymphohistiocytosis and a potentially 
fatal complication characterized by unremitting fever, 
pancytopenia, liver failure with coagulopathy, and cen-
tral nervous system dysfunction (14). Several months be-
fore referral, she was brought for care again with possible 
MAS; symptoms and signs included fever, hepatomegaly, 
diarrhea, anemia, thrombocytopenia, high serum ferritin 
(5,670 µg/L [reference 20–60 µg/L]), albeit with leukocy-
tosis and normal clotting (16). She was treated with IVMP 
and high-dose intravenous immunoglobulin. A previous-
ly inserted CVC was removed because of Enterobacter 
intermedius infection. Because her disease was never in 
full remission (JADAS-10 score 20–30; Table 1), she was 
referred on May 27, 2004, for HSCT (Table 2). On June 1 
(one week after new CVC insertion), she was admitted with 
fever (38°C), macular erythematous rash, vomiting, swell-
ing and pain of several joints, and cough (Table 2). Chest 
examination and radiographic findings were normal, and 
she was treated empirically with systemic antimicrobial 
drugs (teicoplanin and meropenem) for 1 week (15) and a 
3-day course of IVMP for presumed MAS. After transient 
improvement during the next few days, on June 6 the child 
again became unwell, with fever (38.5°C), rash, hepato-
megaly, and joint pain (Table 2). Empirical treatment with 
systemic antimicrobial drugs (teicoplanin and ceftriaxone) 
was restarted with another 3-day course of IVMP, but she 
remained febrile (38.5°C) and became restless with ab-
dominal pain and vomiting. She was transferred to the pe-
diatric intensive care unit (PICU), where surgical reasons 
for acute abdomen pain were excluded. Ciprofloxacin and 
ambisome were added to the treatment regimen, but the 
child’s condition rapidly progressed into multiorgan fail-
ure (Table 2), and she died on June 10. Multiple peripheral 
blood and CVC cultures taken during this period remained 
sterile. The family did not agree to autopsy. Culture from 
the CVC tip removed postmortem grew coagulase-negative 
Staphylococcus.
Patients 3 and 4
Both children received immunosuppressive conditioning 
with anti–T-cell globulin (rabbit, 10 mg/kg), fludarabine (150 
mg/m2), and cyclophosphamide (120 mg/kg) (10,11). Both 
died during T-cell–depleted (by CD34+ positive selection; 
Miltenyi Biotec, San Diego, CA, USA) autologous HSCT.
Patient 3
Patient 3 was an 18-year-old woman whose So-JIA was di-
agnosed at 10 years of age. She had active systemic disease, 
1722 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016
 
Table 2. Laboratory parameters of inflammatory activity for 2 children with juvenile idiopathic arthritis, Newcastle upon Tyne, United 
Kingdom, 2004* 
Patient no., date 
CRP, 
mg/dL 
Ne, × 109 
cells/L 
PLT, × 
109/L 
ESR, 
mm/h 
Ferr, 
μg/L Fib, g/L 
TG, 
mmol/L Alb, g/L ALT, U/L 
Na, 
mmol/L 
Patient 1           
 Feb 17 100 20.2 322 35 485 5.4 0.7 34 24 142 
 Feb 28 107 28.5 266 – – – – 31 35 136 
 Feb 29 157 15.8 140 – – – – 22 48 134 
 Mar 1 63 7.1 79 – – – – 23 120 140 
Patient 2           
 May 27 122 17.2 475 45 339 6.3 1.9 44 10 135 
 Jun 1 260 34.9 603 – 2815 8.0 – 38 23 137 
 Jun 6 365 37.5 710 105 7692 8.1 – 37 50 134 
 Jun 10 127 70.5 244 – – 2.9 – 13 125 134 
*Laboratory parameters for diagnosing macrophage activation syndrome: Ferr >684 g/L and any 2 of the following signs: PLT count <181 × 109/L, ALT 
>48 U/L, TG >156 mg/dL, fibrinogen <360 mg/dL (14). See section in text on MAS versus Multiorgan Failure. Alb, serum albumin level (reference 38–53 
g/L); ALT, serum alanine transaminase level (reference 0–40 U/L); CRP, C-reactive protein (reference 0–5 mg/dL); ESR, erythrocyte sedimentation rate 
(Westergren; reference 1–10 mm/h); Ferr, serum ferritin level (reference 20–60 g/L); Fib, serum fibrinogen level (reference 1.5–4.0 g/L); Na, serum 
sodium level (reference 135–145 mmol/L); Ne, absolute neutrophil count; PLT, absolute platelet count; TG, serum triglyceride level (reference 0.5–1.8). 
 
Infection and Juvenile Idiopathic Arthritis
MAS, and progressive polyarthritis refractory to convention-
al (corticosteroids, methotrexate, cyclosporine, leflunomide) 
and biological DMARDs, both TNF-α (infliximab, etaner-
cept) and IL-1 (anakinra) inhibitors (JADAS-10 score over 
the years 22–35). She underwent HSCT in 2007 with MAS 
prevention (prednisolone, cyclosporine, and anakinra) dur-
ing conditioning, but after uneventful engraftment, she died 
2.5 months after HSCT of disseminated adenovirus (blood, 
feces, brain) and Epstein-Barr virus (EBV) (blood, cerebro-
spinal fluid) infection/reactivation. Aspergillus fumigatus 
was grown from a paranasal sinus washout sample in termi-
nal stage; autopsy was not performed (10).
Patient 4
Patient 4 was a 13-year-old girl whose rheumatoid factor + 
poly-JIA was diagnosed at 4 years of age. She had progres-
sive and debilitating polyarthritis refractory to conventional 
(corticosteroids, methotrexate) and biological (infliximab, 
etanercept, anakinra, rituximab) DMRADSs (JADAS-10 
score over the years 24–30). She underwent HSCT in 2009. 
α-hemolytic Streptococcus grew from CVC culture taken 
during a febrile episode after receipt of anti–T-cell globu-
lin, and she was treated empirically with meropenem and 
teicoplanin; unusually, she rapidly progressed into multior-
gan failure requiring ventilatory, inotropic, and renal sup-
port in the PICU. Because results of initial liver function 
tests, including clotting, were normal, and C-reactive pro-
tein (CRP) response was adequate, the impression was of 
bacterial (or fungal) septicemia and renal failure. After tran-
sient improvement, she completed conditioning and HSCT 
and, despite renal failure, maintained stable neutrophil 
engraftment but remained platelet dependent. Bone mar-
row biopsy was hypocellular and showed some evidence of 
macrophage activation. Subsequently, and in parallel with 
acute pancreatitis, encephalopathy, and progressive enteral 
and liver failure, the girl manifested prolonged hyperin-
flammatory response (CRP 100–170 mg/L [reference 0–5 
mg/L]; fibrinogen 6–10 g/L [reference 1.5–4.0 g/L]; raised 
neutrophil count >20 × 109 cells/L) despite broad-spectrum 
antimicrobial and antifungal therapy. Multiple cultures and 
viral PCRs from different sites (blood, CVC, and other line 
tips; bone marrow and intestine biopsy; cerebrospinal fluid; 
maxillary sinus washing) remained negative. She died on 
day 43 after HSCT; autopsy confirmed multiorgan failure 
with severe secondary pancreatitis (11).
Possible Risk Factors for Severe Infection  
and Death
Treatment with Combined DMARDs,  
Including Biologicals
At death, patients 1 and 2 had active disease treated with 
high-dose systemic corticosteroids and methotrexate; 
because they previously had been exposed to long-term 
and multiple DMARDs, including anti–TNF-α biologi-
cals (Table 1). Patients 3 and 4 underwent autologous T-
cell–depleted HSCT after a severely immunosuppressive 
conditioning regimen.
Clinical observation of increased risk from severe in-
fections in children with JIA, often requiring treatment in a 
hospital (17), recently was confirmed in a study of a large 
JIA cohort (18). The increased risk for concurrent immuno-
suppressive therapy, in addition to the underlying disease-
related immune dysfunction (8,17), was supported by this 
study, in which high-dose systemic corticosteroids, but not 
methotrexate and/or anti–TNF-α agents, substantially in-
creased susceptibility to severe infections (18). Although 
simultaneous use of different biological DMARDs is not 
common (5,6), a recently published study highlighted the 
exposure to multiple and often combined immunosuppres-
sive drugs, such as corticosteroids, methotrexate, cyclospo-
rine, cyclophosphamide, and a variety of biological anti-
inflammatory DMARDs, including TNF-α, IL-1, and IL-6 
blocking agents, as a major risk factor for severe infections 
and the unusually high rate of death for a selected group 
of children with refractory So-JIA, often complicated by 
MAS, and associated with pulmonary hypertension, in-
terstitial lung disease, and alveolar proteinosis (19). It is 
well recognized that severe immunosuppression targeting 
B- and/or T-lymphocyte functions (e.g., B-cell–depleting 
agents, such as rituximab, T-cell activation blocking agent 
abatacept, anti-CD52 monoclonal antibody alemtuzumab, 
HSCT procedure) is often complicated with infections 
caused by a wide spectrum of pathogens, such as pyogenic 
bacteria, viruses, and fungi (7,9–11). In contrast, blocking 
specific inflammatory pathways (e.g., IL-1, IL-6, TNF-α) 
mimics some of the very rare primary immunodeficiencies 
of the innate immune system (20), with susceptibility to 
a relatively narrow range of pathogens (21,22). Infections 
with encapsulated pyogenic bacteria have been reported in 
patients with deficiencies of IL-6 function (23), whereas 
the essential role of TNF-α in defense against intracellular 
pathogens (24) was highlighted by the initially observed 
increased risk for mycobacterial infections associated with 
anti–TNF-α biologicals (7,12), prompting the introduction 
of effective screening and prevention measures (24). Al-
though inconsistently reported (25), unusually prolonged, 
severe, and life-threatening infections with common bacte-
rial pathogens are being seen in children with JIA treated 
with combined DMARDs, including anti–TNF-α agents 
(26,27). As observed in these patients (23,28), because of 
blocking of the inflammatory response mediated by TNF-α, 
IL-1, or IL-6 cytokines, these patients might not have high 
fever and raised CRP, a fact of which clinicians should be 
aware (20–24,29). Regardless of active disease and com-
bined immunosuppressive therapy, patients 1 and 2 (i.e., 
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those not undergoing HSCT) had preserved inflammatory 
responses (Table 2) and appropriate routine immunologic 
testing (data not shown).
CVC-Related Bacterial Infections
Three patients died of CVC-related bacterial sepsis with 
α-hemolytic Streptococcus and coagulase-negative Staphy-
lococcus, common and fully sensitive organisms, despite 
timely administered appropriate antimicrobial therapy (15). 
Long-term CVCs are essential for patients requiring fre-
quent blood tests and intravenous treatments. Unfortunate-
ly, CVC-related bloodstream infection is a well-recognized 
and potentially severe complication. Coagulase-negative 
Staphylococcus species are the most common pathogens 
causing CVC-related infections. Guidelines recommend 
treatment with 10–14 days of systemic antimicrobial drugs 
and antibiotic locks, but routine CVC removal is not recom-
mended because most patients have a benign course and 
rarely develop sepsis or poor outcome (15). S. aureus, en-
teric gram-negative bacilli and Candida are less frequent 
but potentially more severe pathogens. Coagulase-negative 
Staphylococcus species (S. epidermidis in particular) were 
the most common (>50%) pathogens identified from 146 
episodes of bacteremia in 64 children with primary immu-
nodeficiencies undergoing HSCT in Great North Children’s 
Hospital, whereas Enterococcus species, gram-negative 
organisms, and Candida were isolated only in few cases 
each (30). Most (80%) episodes were successfully treated 
with appropriate systemic and antibiotic locks; CVC was 
removed in 12 patients, and the only death resulted from 
overwhelming C. albicans infections despite CVC removal 
(30). Contrary to that study, severe and life-threatening 
CVC-related sepsis caused by S. epidermidis has been re-
ported in a significant percentage of children with systemic 
vasculitis treated with infliximab and combined immuno-
suppressive and/or antiinflammatory therapies (31). Two 
deaths from CVC-related sepsis resulting from coagulase-
negative Staphylococcus and combined Escherichia coli and 
Candida infection were reported from a cohort of children 
with inflammatory bowel disease treated with adalimumab 
in combination with other immunosuppressive medications 
(32). This high risk for severe CVC-related infections as-
sociated with active disease that requires multiple immu-
nomodulatory therapies was also reported from a group of 
children with pediatric rheumatic disease–related complica-
tions admitted to PICU, with substantially high rate of death 
(50%), of which 44% resulted from multiorgan failure (33).
MAS versus Multiorgan Failure
Because the 3 patients we describe who died of CVC-relat-
ed bacterial sepsis manifested unusually severe and rapidly 
progressing multiorgan failure, we considered the possi-
bility of MAS in the differential diagnoses (14,16,33,34). 
MAS is a well-recognized major risk factor for death in 
children with JIA admitted to PICU (33,34). A recent inter-
national study of a large cohort of So-JIA patients identified 
the most common clinical features as fever, organomegaly, 
central nervous system involvement, and hemorrhage (16). 
The most useful laboratory parameters were thrombocy-
topenia; hyperferritinemia; increased liver transaminases, 
lactate dehydrogenase, triglycerides, and D-dimer levels; 
and decreased leukocyte count, erythrocyte sedimentation 
rate, and fibrinogen (16).
Some features that manifested near death, such as per-
sisting fever, falling neutrophil and platelet counts, and in-
creased serum transaminase levels (Table 2; patient 1 on 
March 1) suggest MAS in patient 1 (16). Unfortunately, not 
all of the laboratory parameters highlighted as essential for 
the clinical diagnosis of MAS were available (14) (Table 
2). However, the fact that she collapsed after CVC was ac-
cessed and that α-hemolytic Streptococcus grew from the 
CVC line tip, lung tissue, and pleural effusion samples af-
ter death favors infection as the cause of death. In patient 
2, persisting fever, hepatomegaly, and high serum ferritin 
level suggested MAS, but increasing platelet and neutro-
phil counts, erythrocyte sedimentation rate, and fibrinogen 
and normal liver transaminase levels did not support MAS 
(14) (Table 2; patient 2 on June 6). Although rapid deterio-
ration to terminal multiorgan failure was associated with 
falling platelet count, deranged liver function, and clotting 
(Table 2; patient 2 on June 10), the high neutrophil count 
suggested overwhelming fungal infection (which cannot be 
ruled out because autopsy was not performed), regardless 
of negative fungal cultures. In patient 4, unusually severe, 
progressive multiorgan failure developed after CVC-relat-
ed sepsis, but normal liver function results and clotting and 
adequate CRP response did not support MAS. Features of 
macrophage activation in bone marrow biopsy were seen 
later in the course of progressive multiorgan failure and in 
parallel with unusual hyperinflammation, suggesting pos-
sible fungal infection. However, multiple cultures from dif-
ferent sites remained negative, and autopsy confirmed se-
vere pancreatitis. In patient 3, disseminated adenovirus and 
EBV infection/reactivation during HSCT led to bone mar-
row aplasia. In the terminal stage of multiorgan failure with 
A. fumigatus infection, results of liver function and clotting 
tests were normal, and inflammatory markers were raised 
(erythrocyte sedimentation rate 80 mm/h [Westergren 
method; reference 1–10 mm/h]; CRP 200 mg/L [reference 
0–5 mg/L]; ferritin 11,000 µg/L [reference 20–60 µg/L]).
Deaths and Reporting Deaths
Although the death rate for JIA has decreased since the 
1970s, 1 of 2 recent studies referring to the period be-
fore the use of biological DMARDs reported a standard-
ized mortality ratio of 3.4 (95% CI 2.0–5.5) for boys and 
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5.1 (95% CI 3.2–7.8) for girls (35). This nationwide co-
hort study from Scotland (1,246 children with JIA during 
1981–2000) reported 39 JIA-associated deaths, for which 
the most common causes were the underlying disease (9 
cases), circulatory complications (8 cases), and respira-
tory complications (6 cases) (35). In the United States, the 
standardized mortality ratio for the JIA pediatric rheuma-
tology mortality database (9,604 children with JIA during 
1992–2001) was lower at 1.8 (95% CI 0.66–3.92), with 6 of 
19 reported deaths occurring among children with So-JIA 
caused by MAS and heart failure (2 each) and infection and 
secondary malignancy (1 each) (36).
In addition to uncontrolled disease activity and its com-
plications, in particular amyloidosis in the past and MAS 
today, several recent reviews highlighted the substantial 
risk for death from severe infections in children with JIA 
who are receiving biological DMARDs (7,8). Most of these 
children were treated with multiple and combined classical 
DMARDs before or alongside biological DMARDs. Al-
though the range of causing pathogens is broad, pyogenic 
bacteria and herpes viruses were the most common (7,8). 
An unexpectedly high death rate (68% [17/25]) in a group 
of children with refractory So-JIA associated with pulmo-
nary complications was recently reported from an interna-
tional group of 25 patients (19). Although disease onset 
ranged from the 1980s onward and most children in the 
cohort had received multiple immunosuppressive and anti-
inflammatory drugs, 19 (76%) diagnoses were made after 
2000; contrary to previous reports (35,36), 68% had been 
exposed to biological DMARDs (19). Strikingly, the cal-
culated death rate for these 19 patients increased by almost 
50% over the figure recently reported from the US pediatric 
rheumatology mortality database for the period up to 2000, 
before the use of biological DMARDs (36).
The regional pediatric rheumatology service at Great 
North Children’s Hospital is closely linked to the national 
center providing expertise in investigating and treating 
children with primary immunodeficiencies for northern 
England and a leading center for HSCT in children with 
severe rheumatic diseases. This database holds ≈1,250 
children in whom JIA has been diagnosed and who were 
treated and followed during 1994–2013; each year, 50–80 
new patients are referred. The calculated death rate for chil-
dren in this cohort is 0.032% (4 patients died during this 
period). Three had So-JIA and 1 rheumatoid factor + poly-
JIA, all with progressive polyarthritis and poorly controlled 
systemic disease for many years, including fever, rash, or-
ganomegaly, and high acute-phase reactants, with features 
of MAS in 2 So-JIA patients (14,16). All died during the 
early 2000s after long-term treatment with multiple and 
combined conventional and biological DMARDs: cortico-
steroids and methotrexate (all 4 children), cyclosporine and 
leflunomide (1 each); anti–TNF-α agents (3 etanercept, 4 
infliximab); IL-1 blocking agent (2 anakinra); and B-cell–
depleting (anti-CD20) monoclonal antibody (1 rituximab). 
Although considered in all 4, only 2 patients underwent 
autologous T-cell–depleted HSCT (10,11). With the exper-
tise in pediatric rheumatology, immunology, and infectious 
diseases available in centers best placed to care for these 
most severe and often refractory cases, fatalities are rare 
but do occur.
Monitoring the safety and reporting the side effects, 
including severe infections and deaths, of new biological 
DMARDs is a priority of national and international patient 
registries and multicenter, international collaborative re-
search consortiums, such as the Childhood Arthritis and 
Rheumatology Research Alliance, Pediatric Rheumatology 
International Trials Organisation, Pediatric Rheumatology 
Collaborative Study Group, and Single Hub and Access 
Point of Care for Pediatric Rheumatic Diseases in Europe 
(37,38). However, reporting of deaths is still inconsistent. 
In children with JIA treated with multiple DMARDs along-
side anti–TNF-α biologicals, a systematic review from 
2013 reported 4 deaths, 3 of which were associated with 
severe infections: 2 treated with etanercept (group A Strep-
tococcus–related purpura fulminans) and 1 with adalimum-
ab (bacterial sepsis); for 1 treated with infliximab, infection 
cause was not given (27). However, Hashkes et al. (8) com-
mented on 6 deaths, all in children treated with combined 
DMARDs, including anti–TNF-α agents, and associated 
with serious infections: 3 treated with etanercept (1 each 
with suspected sepsis, MAS, and tuberculosis [previously 
treated with infliximab]); 2 with infliximab (sepsis); and 
1 with adalimumab (MAS and interstitial pneumonia). 
Furthermore, neither Woerner and Ritz (7) nor Swart et 
al. (24) referred to severe infections and infection-related 
deaths associated with biological DMARDs from 2 clinical 
trials reported in 2012 (39,40). Six deaths were reported in 
trials of the anti–IL-6 agent tocilizumab, including 1 each 
from probable streptococcal sepsis and MAS (other listed 
causes were traffic accident, pulmonary hypertension [2 
cases], and pneumothorax) (40). Two deaths were report-
ed in a trial of long-acting anti–IL-1 agent canakinumab, 
both from MAS (1 was previously treated with anakinra 
and tocilizumab) (39). All these patients had active dis-
ease and had been treated with a combination of multiple 
DMARDs before or at death; some were reported as part 
of the So-JIA cohort associated with pulmonary complica-
tions and high death rate (19). The most recent report from 
the United States for 2008–2012 highlighted 7 deaths (1 
from an accident) in children with JIA treated with mul-
tiple DMARDs (methotrexate and steroids), including bio-
logicals (4 anakinra, 1 each etanercept and infliximab), of 
which 3 were associated with severe infections (multiorgan 
failure from disseminated tuberculosis, viral illness, and 
sepsis) (38).
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Conclusions
Three patients with refractory JIA reported here died with 
evidence of CVC-related bacterial sepsis caused by com-
mon pathogens (α-hemolytic Streptococcus and coagulase-
negative Staphylococcus): 2 while receiving high-dose 
systemic corticosteroids; and methotrexate and after recent 
exposure to the anti–TNF-α biological DMARD inflix-
imab; 1 during HSCT procedure. As has been previously 
reported, we observed unusual severity of septic shock 
and rapid progression to multiorgan failure despite timely 
and appropriate antimicrobial treatment (31–33). Patient 4 
died of disseminated adenovirus and EBV infection during 
HSCT procedure.
Evidence from clinical trials facilitated by multicenter 
international collaborative research enabled introduction 
of biological DMARDs in the treatment of rheumatic dis-
eases in children and unprecedented improvement in their 
care during the past 20 years (1–4,41,42). However, se-
vere infections are emerging as an important risk factor 
for death among children with JIA treated with combined 
and multiple conventional and new biological DMARDs 
(8,19,37,38). Accurately reporting all cases of severe in-
fections and especially deaths in these children is of para-
mount importance, as was highlighted a decade ago (25). 
Although monitoring safety and reporting side effects 
of new biological DMARDs is in place and improving, 
we note marked inconsistency in the current literature 
(7,8,19,24,27,38–40).
Acknowledgment
We are grateful to the Paediatric Rheumatology Teams in  
Liverpool and Glasgow, and the Paediatric Intensive Care  
Unit Team, Great North Children’s Hospital, for providing 
excellent clinical care, and to Andrew Riordan and Athimalaipet 
V. Ramanan for helpful discussion.
M.W., M.F., T.J.F., H.E.F., and M.A. were involved in direct 
patient care. M.W., M.F., J.L., and M.A. collected the data.  
J.L. and M.A. had full access to all of the data in the study and 
take responsibility for the integrity of the data and the accuracy of 
the data analysis and interpretation. M.A. wrote the manuscript. 
All authors read and approved the final version to be published 
and had input in revising it for intellectual content and style.
This work was supported by the National Institute for Health 
Research Financial Management Group Flexibility and  
Sustainability Funding (ref. FSF 121301 to M.A.).
Dr. Abinun is a senior consultant in pediatric immunology at Great 
North Children’s Hospital and an honorary clinical senior lecturer 
at Newcastle University, Institute of Cellular Medicine, Primary 
Immunodeficiency Group. His research interests include primary 
immunodeficiency, autoimmune and auto inflammatory diseases, 
and treatment with hematopoietic stem cell transplantation.
References
  1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. 
Lancet. 2011;377:2138–49. http://dx.doi.org/10.1016/S0140-
6736(11)60244-4 
  2. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic 
arthritis: hitting the target. Nat Rev Rheumatol. 2015;11:290–300. 
http://dx.doi.org/10.1038/nrrheum.2014.212 
  3. Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, 
Kimura Y, et al.; American College of Rheumatology. 2013 update 
of the 2011 American College of Rheumatology recommendations 
for the treatment of juvenile idiopathic arthritis: recommendations  
for the medical therapy of children with systemic juvenile 
idiopathic arthritis and tuberculosis screening among children 
receiving biologic medications. Arthritis Care Res (Hoboken). 
2013;65:1551–63. http://dx.doi.org/10.1002/acr.22087 
  4. Southwood TR. Paediatric rheumatic disease: treatment of JIA in 
the biologic era: what are we waiting for? Nat Rev Rheumatol. 
2014;10:132–4. http://dx.doi.org/10.1038/nrrheum.2014.14 
  5. Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Arm-
brust W, et al. Effectiveness and safety of a second and third bio-
logical agent after failing etanercept in juvenile idiopathic arthritis: 
results from the Dutch National ABC Register. Ann Rheum Dis. 
2013;72:721–7. http://dx.doi.org/10.1136/annrheumdis-2011-201060 
  6. Record JL, Beukelman T, Cron RQ. Combination therapy of  
abatacept and anakinra in children with refractory systemic  
juvenile idiopathic arthritis: a retrospective case series.  
J Rheumatol. 2011;38:180–1. http://dx.doi.org/10.3899/
jrheum.100726 
  7. Woerner A, Ritz N. Infections in children treated with  
biological agents. Pediatr Infect Dis J. 2013;32:284–8.  
http://dx.doi.org/10.1097/INF.0b013e3182833cbb 
  8. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic 
therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 
2010;6:561–71. http://dx.doi.org/10.1038/nrrheum.2010.142 
  9. Abinun M. Haematopoietic stem cell transplantation for  
rheumatological conditions. Paediatr Child Health. 2011;21:558–
62. http://dx.doi.org/10.1016/j.paed.2011.06.003
10. Abinun M, Flood TJ, Cant AJ, Veys P, Gennery AR, Foster HE,  
et al. Autologous T cell depleted haematopoietic stem cell  
transplantation in children with severe juvenile idiopathic  
arthritis in the UK (2000–2007). Mol Immunol. 2009;47:46–51. 
http://dx.doi.org/10.1016/j.molimm.2008.12.029 
11. Milanetti F, Abinun M, Voltarelli JC, Burt RK. Autologous  
hematopoietic stem cell transplantation for childhood  
autoimmune disease. Pediatr Clin North Am. 2010;57:239–71.  
http://dx.doi.org/10.1016/j.pcl.2009.12.003 
12. Myers A, Clark J, Foster H. Tuberculosis and treatment with  
infliximab. N Engl J Med. 2002;346:623–6.  
http://dx.doi.org/10.1056/NEJM200202213460815 
13. Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, 
Pistorio A, et al.; Paediatric Rheumatology International Trials 
Organization (PRINTO). Defining criteria for high disease activity 
in juvenile idiopathic arthritis based on the juvenile arthritis disease 
activity score. Ann Rheum Dis. 2014;73:1380–3.  
http://dx.doi.org/10.1136/annrheumdis-2013-204186 
14. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 
2016 classification criteria for MAS complicating SO-JIA:  
EULAR/ACR/PPRINTO Initiative. Arthritis Rheumatol. 
2016;68:566–76. http://dx.doi.org/10.1002/art.39332 
15. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P,  
O’Grady NP, et al. Clinical practice guidelines for the diagnosis and 
management of intravascular catheter-related infection:  
2009 update by the Infectious Diseases Society of America. Clin 
Infect Dis. 2009;49:1–45. Erratum in: Clin Infect Dis. 2010;50:457. 
Erratum in: Clin Infect Dis. 2010;50:1079. http://dx.doi.
org/10.1086/599376 
1726 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016
Infection and Juvenile Idiopathic Arthritis
16. Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al.; 
Pediatric Rheumatology International Trials Organization;  
Childhood Arthritis and Rheumatology Research Alliance;  
Pediatric Rheumatology Collaborative Study Group; Histiocyte 
Society. Clinical features, treatment, and outcome of macrophage 
activation syndrome complicating systemic juvenile idiopathic 
arthritis: a multinational, multicenter study of 362 patients. Arthritis 
Rheumatol. 2014;66:3160–9. http://dx.doi.org/10.1002/art.38802 
17. Lovell DJ, Zaoutis TE, Sullivan K. Immunosuppressants,  
infection, and inflammation. Clin Immunol. 2004;113:137–9.  
http://dx.doi.org/10.1016/j.clim.2004.03.010 
18. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, 
et al.; SABER Collaboration. Rates of hospitalized bacterial infection 
associated with juvenile idiopathic arthritis and its treatment. 
Arthritis Rheum. 2012;64:2773–80. http://dx.doi.org/10.1002/
art.34458 
19. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, 
et al.; Childhood Arthritis Rheumatology Research Alliance Carra 
Net Investigators. Pulmonary hypertension and other potentially 
fatal pulmonary complications in systemic juvenile idiopathic 
arthritis. Arthritis Care Res (Hoboken). 2013;65:745–52.  
http://dx.doi.org/10.1002/acr.21889 
20. van de Vosse E, van Dissel JT, Ottenhoff TH. Genetic deficiencies 
of innate immune signalling in human infectious disease. Lancet 
Infect Dis. 2009;9:688–98. http://dx.doi.org/10.1016/S1473-
3099(09)70255-5 
21. Abinun M. An overview of infectious complications in children 
on new biologic response-modifying agents. Pediatric Health. 
2010;4:509–17. http://dx.doi.org/10.2217/phe.10.57
22. Maródi L, Casanova JL. Primary immunodeficiencies may reveal 
potential infectious diseases associated with immune-targeting 
mAb treatments. J Allergy Clin Immunol. 2010;126:910–7.  
http://dx.doi.org/10.1016/j.jaci.2010.08.009 
23. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. 
Recurrent staphylococcal cellulitis and subcutaneous abscesses in a 
child with autoantibodies against IL-6. J Immunol. 2008;180:647–
54. http://dx.doi.org/10.4049/jimmunol.180.1.647 
24. Swart JF, de Roock S, Wulffraat NM. What are the immunological 
consequences of long-term use of biological therapies for  
juvenile idiopathic arthritis? Arthritis Res Ther. 2013;15:213.  
http://dx.doi.org/10.1186/ar4213 
25. Fitch PG, Cron RQ. Septic abscess in a child with juvenile 
idiopathic arthritis receiving anti-tumor necrosis factor-alpha.  
J Rheumatol. 2006;33:825, author reply 826–7.
26. Renaud C, Ovetchkine P, Bortolozzi P, Saint-Cyr C, Tapiero B. 
Fatal group A Streptococcus purpura fulminans in a child  
receiving TNF-α blocker. Eur J Pediatr. 2011;170:657–60.  
http://dx.doi.org/10.1007/s00431-010-1341-1 
27. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children 
and adolescents with juvenile idiopathic arthritis and inflammatory 
bowel disease treated with tumor necrosis factor-α inhibitors:  
systematic review of the literature. Clin Infect Dis. 2013;57:1318–
30. http://dx.doi.org/10.1093/cid/cit489 
28. Elwood RL, Pelszynski MM, Corman LI. Multifocal septic 
arthritis and osteomyelitis caused by group A Streptococcus in 
a patient receiving immunomodulating therapy with etanercept. 
Pediatr Infect Dis J. 2003;22:286–8. http://dx.doi.org/10.1097/01.
inf.0000055092.90609.e5 
29. Henderson C, Goldbach-Mansky R. Monogenic IL-1 mediated 
autoinflammatory and immunodeficiency syndromes:  
finding the right balance in response to danger signals.  
Clin Immunol. 2010;135:210–22. http://dx.doi.org/10.1016/j.
clim.2010.02.013 
30. Cole TS, Rogerson E, Collins J, Galloway A, Clark J. Central 
venous catheter-related blood stream infections in children  
undergoing hematopoietic stem cell transplant for primary  
immunodeficiency and other nonmalignant disorders.  
Pediatr Infect Dis J. 2011;30:1098–100. http://dx.doi.org/10.1097/
INF.0b013e31822940a8 
31. Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G,  
et al. Biologic therapy in primary systemic vasculitis of  
the young. Rheumatology (Oxford). 2009;48:978–86.  
http://dx.doi.org/10.1093/rheumatology/kep148 
32. Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, 
Mahdi G, et al. A British Society of Paediatric Gastroenterology, 
Hepatology and Nutrition survey of the effectiveness and safety of 
adalimumab in children with inflammatory bowel disease. Aliment 
Pharmacol Ther. 2011;33:946–53. http://dx.doi.org/10.1111/j.1365-
2036.2011.04603.x 
33. Radhakrishna SM, Reiff AO, Marzan KA, Azen C, Khemani RG, 
Rubin S, et al. Pediatric rheumatic disease in the intensive care 
unit: lessons learned from 15 years of experience in a tertiary care 
pediatric hospital. Pediatr Crit Care Med. 2012;13:e181–6.  
http://dx.doi.org/10.1097/PCC.0b013e318238955c 
34. Shulman AI, Punaro M. Critical care of the pediatric patient  
with rheumatic disease. Curr Opin Pediatr. 2011;23:263–8.  
http://dx.doi.org/10.1097/MOP.0b013e328346198f 
35. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. 
National study of cause-specific mortality in rheumatoid arthritis, 
juvenile chronic arthritis, and other rheumatic conditions: a 20 year 
followup study. J Rheumatol. 2003;30:958–65.
36. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, 
Roettcher PA, et al. Mortality outcomes in pediatric rheumatology 
in the US. Arthritis Rheum. 2010;62:599–608.
37. Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, 
Ilowite NT, et al. Using registries to identify adverse events in 
rheumatic diseases. Pediatrics. 2013;132:e1384–94.  
http://dx.doi.org/10.1542/peds.2013-0755 
38. Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, 
Bohnsack J, et al. Novel method to collect medication adverse 
events in juvenile arthritis: results from the childhood arthritis and 
rheumatology research alliance enhanced drug safety surveillance 
project. Arthritis Care Res (Hoboken). 2015;67:529–37.  
http://dx.doi.org/10.1002/acr.22487 
39. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, 
Horneff G, et al.; PRINTO; PRCSG. Two randomized trials of 
canakinumab in systemic juvenile idiopathic arthritis.  
N Engl J Med. 2012;367:2396–406. http://dx.doi.org/10.1056/
NEJMoa1205099 
40. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, 
Calvo I, et al.; PRINTO; PRCSG. Randomized trial of  
tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 
2012;367:2385–95. http://dx.doi.org/10.1056/NEJMoa1112802 
41. van Royen-Kerkhof A, Vastert BS, Swart JF, Wulffraat NM. 
Biologic treatment of pediatric rheumatic diseases: are we spoilt 
for choice? Immunotherapy. 2014;6:1–3. http://dx.doi.org/10.2217/
imt.13.153 
42. Wahezi DM, Ilowite NT. Juvenile idiopathic arthritis: an update 
on current pharmacotherapy and future perspectives. Expert Opin 
Pharmacother. 2013;14:975–89. http://dx.doi.org/10.1517/1465656
6.2013.783569 
Address for correspondence: Mario Abinun, Great North Children’s 
Hospital, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon 
Tyne, NE1 4LP, UK; email: mario.abinun@ncl.ac.uk
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016 1727
